Validation of the FEW16 questionnaire for the assessment of physical well-being in patients with heart failure with reduced ejection fraction: results from the CIBIS-ELD study

E. Tahirović1, D. J. Lashk1, T. D. Trippel1,2, V. Tscholl3, M. Fritschka1, L. Musial-Bright1, A. Busjahn4, P. Kolip5, S. Störk6, M. Rauchfuß7, S. Inkrot1, M. Lainscak8,9, S. Apostolović10, J. Vesković1, G. Lončar11, W. Doehner12, C. Zelenak1 and H. D. Dünge1

1Department of Internal Medicine – Cardiology, Charité University Medicine Berlin, Germany; 2German Center for Cardiovascular Research (DZHK), Site Berlin, Germany; 3Medical Clinic for Cardiology and Pulmonology, Campus Benjamin Franklin, Charité University Medicine Berlin, Germany; 4HealthTwiSt GmbH, Berlin, Germany; 5Department of Prevention and Health Promotion, School of Public Health, Bielefeld University, Bielefeld, Germany; 6Comprehensive Heart Failure Center, University of Würzburg, Germany; 7Centre of Internal Medicine and Dermatology, Clinic for Internal Medicine and Psychosomatics, Charité University Medicine Berlin, Germany; 8Department of Cardiology and Department of Research and Education, General Hospital Celje, Slovenia; 9Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia; 10Clinical Center Niš, Department of Internal Medicine, University of Niš, Serbia; 11Cardiology Department, Zvezdara University Medical Center, Belgrade, Serbia; 12Center for Stroke Research, Charité University Medicine Berlin, Germany

Abstract

Aims Patients with heart failure (HF) commonly suffer from severe impairment of quality of life (QoL). One main goal of HF treatment is improvement of QoL. Physical well-being is an essential component of QoL. To enable assessment of physical well-being in HF patients, we validated the FEW16 questionnaire in a prospective study with patients from the Cardiac Insufficiency Bisoprolol Study in ELDerly.

Methods and results In 127 HF patients (age 73 ± 5.5 years, 72% male, 60% New York Heart Association class II, left ventricular ejection fraction 37 ± 8.5%), we measured physical well-being (FEW16), QoL [36-Item Short-Form Health Survey (SF36)], and depressive symptoms [PRIME MD Patient Health Questionnaire German short version for depression (PHQ-D)] at baseline and two follow-up visits, and correlated FEW16 scores with QoL data and clinical parameters. FEW16 mean scores are 3.04 ± 1.04 at baseline, 3.19 ± 0.94 after 3 months, and 2.77 ± 0.94 after 2–4 years. We assessed data quality, scale assumptions, and construct validity and reliability. Cronbach’s alpha for subscales resilience: 0.84; ability to enjoy: 0.80; vitality: 0.88; inner peace: 0.87; total score: 0.95. Intraclass correlation coefficient (ICC) is 0.87 (95% CI 0.84–0.89, ICC (1.4). Pearson’s correlations of FEW16 with SF36 and PHQ-D were significant. Six minutes walking distance and heart rate correlated significantly with the FEW16 total score.

Conclusions The FEW16 showed good reliability, internal consistency, and intraclass correlation. FEW16 scores correlated well with psychological and physical well-being (SF36) and clinical markers of exercise tolerance (6 min walk test and heart rate). Our results indicate a strong correlation of self-reported physical well-being with psychological factors. FEW16 values at baseline predicted the development of several aspects of QoL during beta-blocker up-titration.

Keywords Heart failure; FEW16; Physical well-being; Quality of life (QoL); Validation

Received: 26 January 2015; Revised: 7 May 2015; Accepted: 19 May 2015

*Correspondence to: Elvis Tahirović, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Tel: +49 30450676817, Fax: +49 30450576913. Email: elvis.tahirovic@charite.de

© 2015 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Introduction

Heart failure (HF) is a globally growing health problem with high rates of mortality and morbidity and associated with considerable impairment in quality of life (QoL). In westernized countries, HF is the most common cause for hospitalization in patients above age 65 years, rendering HF one of the principal burdens for health care systems in the 21st century. Besides morbidity and mortality, QoL has been identified as one major patient-reported outcome (PRO). and poor QoL in HF has been associated with reduced survival.

Patient’s health status significantly impacts on QoL, which includes mental, physical, and social aspects of life. Impairment of QoL through illness may lead to depression, social isolation, and diminished adherence to therapy. On the other hand, the potentially causal associations are bi-directional: treatment itself (e.g. betablocker therapy) may affect QoL, and ‘objective clinical improvement’ may differ from the ‘subjective well-being’ of patients.

The European Society of Cardiology emphasizes the necessity to study PROs as endpoints in clinical studies because—from a patient perspective—they bear similar relevance compared with morbidity and mortality and may thus be regarded complementary endpoints. Disease management in HF should be directed not only to prolong life but also to enhance the patient’s well-being and QoL. In this respect, PRO data reflecting the subjective experience of treated patients may serve well in the decision-making process of the therapeutic strategy.

Ideally, a self-report by the patient should serve several purposes: help the caring team in the patient assessment, assure the patient that he or she is being perceived as an individual in a holistic treatment approach, and raise patient’s awareness about his or her health condition. However, the clinical utility of a patient questionnaire not only depends on the number and phrasing of questions, but also on the subject’s general condition present when filling in the questionnaire. In patients with HF, comorbid conditions (e.g. depressed mood) have major confounding role. It is thus important to validate questionnaires for use in specific subpopulations and to include the knowledge and input of those patients into its design process.

The aim of the presented work was to further validate the questionnaire for subjective physical well-being (FEW16 - Fragebogen für die Erhebung des körperlichen Wohlbefindens) for its use in patients with systolic HF.

Methods

Ethical approval of the study and informed consent

The investigation conforms to the principles outlined in the Declaration of Helsinki. The German Health Authorities and the Ethics Committees at each centre approved the study. Written informed consent was obtained from all patients prior to any study-related procedures.

Study population

For the current report we sampled 136 patients from the Cardiac Insufficiency Bisoprolol Study in ELDerly (CIBIS-ELD) study, a randomized prospective trial investigating the differential impact of betablockers in elderly patients with heart failure with reduced (or preserved) left ventricular ejection fraction (LVEF). The study design has been reported in detail elsewhere. Briefly, eligible patients were ≥65 years of age, diagnosed with symptomatic HF (i.e. NYHA functional class ≥ II) or LVEF ≤45% and had stable symptoms in the last 2 weeks prior to inclusion. After obtaining written consent for this study, we measured the physical and psychological well-being by use of the FEW16 as well as the QoL [36-Item Short-Form Health Survey (SF36)] and depressive symptoms [PRIME MD Patient Health Questionnaire German short version (PHQ-D)].

Data collection and instruments

We collected data at trial baseline (i.e. the start of beta-blocker up-titration) and after 3 months of follow-up (FU1). Additional data were collected 2 to 4 years after baseline (FU2) to gather longitudinal information. All questionnaires were completed by the patients themselves in the outpatient department without supervision.

FEW16

In order to adapt this concept of salutogenesis by Aaron Antonovsky, Kolip & Schmidt developed the FEW16, a 16-item ‘Questionnaire for assessing Physical Well-being’, with a particular emphasis on positive phrasings, because previous questionnaires rather focused on inabilities and pain. The FEW16 measures the subjective habitual physical well-being through the last 3 weeks by concentrating on the psychological well-being in the sense of affective experiencing and abilities rather than on the absence of disease, pain, or physical incapacity. The habitual well-being is perceived as a construct, which is relatively stable over weeks to months. It relies on the assessment of emotional experiences and is thus influenced by also stable personality traits and the subject’s environment. The FEW16 questionnaire has been validated using two patient populations from a rehabilitation centre and one sample population of healthy university students. Albani et al. 2006 applied the FEW16 in healthy samples of 573 subjects from East and 1900 subjects from West Germany. Their results speak for a good reliability and internal consistency of the FEW16 questionnaire.

The FEW16 consists of four subscales: Resilience, Ability to Enjoy, Vitality, and Inner Peace, each of which contains four items. The items are to be answered on a 6-point Likert scale...
with answer options ranging from ‘fully applies’ (yielding 5 points) to ‘does not apply at all’ (yielding 0 points). Higher scores indicate better physical well-being. The subscale values are calculated as mean of the values for the four subscale items. Per subscale, a maximum of one erroneous value can be substituted by the mean of the subscale. The total score is calculated as the mean of the four subscale values. High values stand for good physical well-being.

**36-Item Short-Form Health Survey**

To estimate the construct validity of the FEW16, we used the German version of the MOS 36-Item Short-Form Health Survey (SF36) by Ware & Sherbourn,21 which is a standard German version of the questionnaire originally developed as the main psychological symptoms in primary medical care,34 PRIME MD Patient Health Questionnaire German short version

The PHQ-D questionnaire was designed for the recognition of depression,6,8–10 pronounced,15–19 or major depression with the distinction of medium,10–14 pronounced,15–19 or severe.20–27 The PHQ-D questionnaire can be answered quickly, is easy to interpret, and has been recognized as valid and reliable.37–39

**Cronbach’s alpha**

Cronbach’s alpha coefficient and Guttman’s lambda6 were calculated. Probability of answering levels per item was estimated via the 25th/75th percentile. For a cross-validation with the SF36 questionnaire and the PHD-Q, Spearman rank correlations were calculated.

The second step of analysis focused on the relations between physical well-being and clinical parameters. Spearman rank correlations were calculated for quantitative values such as the distance in the 6 min walking test (6MWT). For categorical data such as sex or NYHA category, the groups were compared using the Kruskal–Wallis rank sum test. In addition to the baseline values of the patients, their changes at a follow-up examination after 4 years were analyzed in order to test the possible prognostic value of the FEW16 scales.

In an exploratory fashion, all correlations were calculated separately for the gender groups after the analysis in the total sample. A formal comparison between the groups by means of inferential statistics was not part of this analysis and would require a greater sample size.

Five per cent was defined as the level for statistical significance. All calculations were made in the statistical scripting language R (http://www.R-project.org/).

**Results**

**Patient sample**

Only patients diagnosed with systolic HF were recruited for this study (LVEF ≤ 45%, n = 136). For 127 of these patients, complete data were available at baseline and thus used for final analysis [mean age 73 ± 5.5 years, 72% male, mean LVEF 37 ± 8.5%, and 5.5%, 59.8%, and 34.7% in NYHA functional class I, II, and III, respectively (Table 2)]. Due to some missing data, we have complete FEW16 and SF36 data for the follow-up after 3 months for 118 patients and for the follow-up after 2–4 years for 44 patients which could be included into the calculations. When calculating changes between data from different time points, we applied pairwise tests, including only patients with valid data at both measurement times.

**FEW16, 36-Item Short-Form Health Survey, and PRIME MD Patient Health Questionnaire German short version questionnaires**

Figure 1 shows the scores of all questionnaires at the different time points. The FEW16 total score increased significantly from 3.04 ± 1.04 at baseline to 3.19 ± 0.94 at FU1. At FU2, the total score had decreased to 2.77 ± 0.94 (P = n.s. compared with baseline). Regarding the subscales, the scores for Ability of internal consistency, intraclass correlations (type 3),
to Enjoy and Vitality increased significantly from baseline to FU1, but changes to FU2 were not significant. Values for all SF36 subscales significantly increased between baseline and FU1. At FU2, scores for General Health perceptions, Role Emotional, and the psychological component score had increased, and Role Physical had decreased significantly. We further detected a significantly reduced total score for the PHQ-D at FU1 when compared with baseline, which returned back to baseline levels at FU2.

**Factorial structure and internal consistency**

The factorial structure of the FEW16 questionnaire showed four factors (Figure 2). Items 1, 5, 8, and 10 are originally assigned to subscale Resilience (PA3). In our dataset, item 8 had a strong relationship to this subscale with a factor loading of 0.47, but was equally related to the scale Ability to Enjoy with a factor loading of 0.48. Because of the numerically

**Table 1 Medical description of the sample all at time points**

| Parameter                                      | Baseline          | 3 months     | 2–4 years  |
|------------------------------------------------|-------------------|--------------|------------|
| Age mean ± SD (years)                          | 73 ± 5.5          | 72/28        | 72/28      |
| Sex male/female (%)                            | 72/28             | 72/28        | 72/28      |
| BMI (kg/m²) ± SD                               | 27.9 ± 4.5        | 28.8 ± 4.6   |            |
| Drinks per week mean ± SD                      | 1.41 ± 3.7        |              |            |
| 6 min walking distance ± SD (m)                | 356 ± 114         | 364 ± 109    | 340 ± 148  |
| Left ventricular ejection fraction mean ± SD   | 37 ± 8.5          | 41 ± 10.2    |            |
| NYHA 1/2/3/4 (%)                               | 5.5/59.8/34.7     | 15.8/67.7/16.5 | 27/57/13/3 |
| Myocardial infarction (%)                      | 46                |              |            |
| Biventricular pacemaker no/yes (%)             | 98/2              |              |            |
| Hypertension (%)                               | 88                |              |            |
| Adipositas (%)                                 | 30                |              |            |
| Diabetes mellitus (%)                          | 26                |              |            |
| Hyperlipidemia (%)                             | 75                |              |            |
| Non-smoker/ex-smoker/smoker (%)                | 52/40/8           |              |            |
| Ace inhibitor (%)                              | 76                | 69           | 69         |
| Betablocker (%)                                 | 58                | 80           | 80         |
| Glykosides (%)                                 | 17                | 9            | 9          |
| Aldosterone antagonists (%)                    | 23                | 18           | 18         |
| Nitrite (%)                                    | 34                | 25           | 25         |
| Statins (%)                                    | 52                | 52           | 52         |
| Aspirin (%)                                    | 69                | 73           | 73         |

SD, standard deviation; NYHA, New York Health Association.

**Figure 1** Mean scores of FEW16, 36-Item Short-Form Health Survey (SF36) and PRIME MD Patient Health Questionnaire German short version (PHQ-D) at all three time points with standard errors. Stars indicate significant difference to baseline. n = 127 at baseline, n = 118 at after 3 months (FU1), n = 44 at 2 to 4 years after baseline (FU2). Pairwise calculation of change significances. *** P < 0.001, ** P < 0.01, * P < 0.05.
Table 2 Statistical key figures of the FEW16 subscales at baseline

| Scale          | Median | 25th/ 75th percentile | Relative part of total variance | Cronbach’s Alpha | Guttmann’s lambda6 | Intercorrelation coefficient type 3 | ICC3 confidence interval |
|----------------|--------|------------------------|---------------------------------|------------------|---------------------|------------------------------------|-------------------------|
| Resilience     | 2.5    | 1.8/3.5                | 0.188                           | 0.836            | 0.828               | 0.561                              | 0.476/0.644             |
| Ability to Enjoy| 3.5    | 2.8/4.5                | 0.202                           | 0.878            | 0.858               | 0.642                              | 0.565/0.714             |
| Vitality       | 3.2    | 2.0/4.0                | 0.123                           | 0.914            | 0.911               | 0.728                              | 0.663/0.786             |
| Inner Peace    | 3.2    | 2.5/4.0                | 0.194                           | 0.900            | 0.897               | 0.692                              | 0.622/0.757             |

We found the strongest correlations of SF36 Vitality for FEW16 Ability to Enjoy and Vitality. Interestingly, the FEW16 total score showed a stronger correlation with the psychological than with the physical component score of the SF36. The psychological component score had the highest correlation with the Inner Peace subscale, almost as strong as with the FEW16 total score. The physical component scale correlated best with FEW16 Vitality. The correlations of the FEW16 scores with those of the PHQ-D were all significant and negative. They were strongest for the PHQ-D subscales Difficulties sleeping, Feeling tired/having little energy, and Feeling down, depressed, hopeless. Here, Difficulties sleeping was most strongly related to FEW16 Vitality. Feeling tired/having little energy correlated most strongly with Ability to enjoy as did Little interest/pleasure in doing things and Poor appetite/overeating. The PHQ-D subscales Thoughts of suicide, Physical impairments, Lack of self-confidence, and Difficulties concentrating all correlated most strongly with FEW16 subscale Inner Peace.

Relation between clinical measurements and FEW16 and presumed gender specificity

Table 4 shows the correlations between clinical data and FEW16 scales. We found significant correlations between the 6MWT and the FEW16 total score (0.24) as well as with the subscales Resilience (0.26), Inner Peace (0.21), and Ability to Enjoy (0.18). In addition, patients’ heart rate showed significant negative correlations with the FEW16 total score (−0.22) and with the subscales Ability to Enjoy (−0.22) and Resilience (−0.20). A tendency was found for Inner Peace and heart rate. Age and LVEF on the other hand did not correlate with any of the FEW16 scales. As for sex, NYHA class, and betablocker therapy, there were no significant correlations with any FEW16 scale either, although tendencies were noted for a correlation between sex and Vitality, Inner Peace and the total FEW16 score, and for NYHA class and Resilience. Major depression correlated significantly with all subscales and with the total FEW16.

Figure 3 shows the potential impact of gender on the relations between FEW16 scales and clinical measurements using the 6MWT as an example. There was a positive relationship between physical well-being (total score FEW16) and the 6MWT, which was detectable in men only.
Aim of this study was the validation of the FEW16 as a disease-specific instrument for the assessment of physical well-being in HF patients. The FEW16 showed good reliability and internal consistency with high values for Guttman’s lambda 6 and Cronbach’s alpha, which were comparable to findings in previous validations.13

**Discussion**

**Validity of FEW16 for assessment of health-related Quality of Life**

Aim of this study was the validation of the FEW16 as a disease-specific instrument for the assessment of physical well-being in HF patients. The FEW16 showed good reliability and internal consistency with high values for Guttman’s lambda 6 and Cronbach’s alpha, which were comparable to findings in previous validations.13

### Relation between changes in FEW16 values and clinical parameters and SF36

We further assessed whether the changes from baseline to FU2 measured by the FEW16 reflected the changes measured by the SF36 and PHQ-D and those of clinical parameters (Table 5). The FEW16 total score changes did not correlate with changes in 6MWT, LVEF, and heart rate, but they reflected the changes of the SF36 subscales General Health Perceptions, Vitality, Social Functioning, Physical Functioning, Mental Health, and the physical and the psychological components. Of the FEW16 subscales, Vitality correlated with SF36 Physical Functioning. Inner Peace was the FEW16 subscale that correlated with more SF36 scales (5 out of 10) than any other with two of those subscales relating to physical QoL (Vitality and Role physical). Resilience correlated with four out of nine SF36 subscales. With regard to depressive symptoms (PHQ-D), changes in the FEW16 total score had significant negative correlations with changes in Little interest/pleasure in doing things, Feeling tired/having little energy, Difficulties sleeping, Physical impairments, and Thoughts of suicide.

### Table 3 Correlation coefficients of FEW16 subscales with the subscales of 36-Item Short-Form Health Survey and the PRIME MD Patient Health Questionnaire German short version instruments at baseline

| Variable | Resilience | Ability to Enjoy | Vitality | Inner Peace | FEW16 |
|----------|------------|------------------|----------|-------------|-------|
| SF36     |            |                  |          |             |       |
| Vitality | 0.666***   | 0.727***         | 0.713*** | 0.628***    | 0.801*** |
| Mental Health | 0.504*** | 0.627***         | 0.532*** | 0.756***    | 0.703*** |
| Social Functioning | 0.491*** | 0.471***         | 0.449*** | 0.534***    | 0.551*** |
| General Health Perceptions | 0.514*** | 0.439***         | 0.443*** | 0.495***    | 0.543*** |
| Role—Physical | 0.522*** | 0.454***         | 0.519*** | 0.343***    | 0.514*** |
| Physical Functioning | 0.460*** | 0.467***         | 0.455*** | 0.384***    | 0.501*** |
| Pain | 0.406*** | 0.403***         | 0.444*** | 0.433***    | 0.474*** |
| Role—Emotional | 0.295**  | 0.311***         | 0.382*** | 0.325***    | 0.385*** |
| Physical, sum | 0.435*** | 0.418***         | 0.476*** | 0.304***    | 0.469*** |
| Psychological, sum | 0.466*** | 0.541***         | 0.540*** | 0.620***    | 0.634*** |
| PHQ-D |            |                  |          |             |       |
| Difficulties sleeping | −0.461*** | −0.576***        | −0.627*** | −0.426***   | −0.618*** |
| Feeling tired or having little energy | −0.501*** | −0.567***        | −0.549*** | −0.412***   | −0.600*** |
| Feeling down, depressed or hopeless | −0.458*** | −0.517***        | −0.449*** | −0.556***   | −0.573*** |
| Little interest or pleasure in doing things | −0.455*** | −0.477***        | −0.392*** | −0.401***   | −0.510*** |
| Thoughts of suicide | −0.390*** | −0.437***        | −0.413*** | −0.529***   | −0.496*** |
| Physical impairments | −0.397*** | −0.434***        | −0.383*** | −0.487***   | −0.469*** |
| Lack of self-confidence | −0.332*** | −0.425***        | −0.370*** | −0.495***   | −0.455*** |
| Difficulties concentrating on things | −0.298*** | −0.435***        | −0.323*** | −0.459***   | −0.438*** |
| Poor appetite or overeating | −0.238**  | −0.410***        | −0.270*** | −0.342***   | −0.365*** |

***P < 0.001, **P < 0.01, *P < 0.05.

SF36, 36-Item Short-Form Health Survey; PHQ-D, PRIME MD Patient Health Questionnaire German short version.

### Table 4 Correlation coefficients of the FEW16 subscales with clinical parameters at baseline

| Variable                      | Resilience | Ability to Enjoy | Vitality | Inner Peace | FEW16 |
|-------------------------------|------------|------------------|----------|-------------|-------|
| Age                           | −0.042     | −0.112           | −0.083   | −0.111      | −0.086 |
| 6 min walking distance        | 0.256 **   | 0.180 *          | 0.139    | 0.207 *     | 0.240 ** |
| LVEF                          | 0.094      | 0.038            | 0.056    | −0.127      | 0.026  |
| Heart Rate                    | −0.196 *   | −0.217 *         | −0.058   | −0.168 +    | −0.216 * |
| Sex                           | n.s.       | n.s.             | +        | +           | +     |
| NYHA                          | +          | n.s.             | n.s.     | n.s.        | n.s.  |
| Betablocker                   | n.s.       | n.s.             | n.s.     | n.s.        | n.s.  |
| Major depression              | ***        | ***              | ***      | ***         | ***   |

***P < 0.001, **P < 0.01, *P < 0.05.

LVEF, left ventricular ejection fraction; NYHA, New York Health Association.
The factorial structure could be reconstructed with one exception, that item 8 appeared to have a slightly stronger association with subscale Ability to Enjoy than with Resilience. Given the high intercorrelation of subscales, all addressing the same generalized factor ‘well-being’, this deviation from the original factor score is not seen as critical problem potentially limiting the questionnaires use. In the original factor analysis defining the subscales, several items showed relevant factor loadings above 0.4 for more than one subscale and were assigned to the scale with the highest loading.

The FEW16 subscales showed significant correlations with all SF36 subscales. Subscales in the different questionnaires expected to measure constructs of the same content showed higher correlations than those measuring different constructs. For example, the finding that FEW16 Vitality correlated strongly with SF36 Vitality, and Physical Functioning confirmed that the FEW16 measured the correct construct in this place. Vitality is an important factor of physical well-being. This result confirms what Kolip & Schmidt found in their first validation study. The negative correlations of the FEW16 scores with those of the PHQ-D were expected as the PHQ-D measures the absence of well-being as opposed to the FEW16. The strong correlation of the FEW16 with depression underlines its validity, as depression is a common comorbidity in HF. In addition, Kolip & Schmidt differentiated between the QoL measured by the SF36 and physical well-being measured by the FEW16 as two different constructs, but agreed to a considerable overlap. For validation, they chose two SF36 subscales, Vitality and Pain, together with two questionnaires that assess back pain. Thus, they concentrated on the physical part of the FEW16. The fact that the FEW16 total score showed a stronger correlation with the psychological than with the physical SF36 component does not contradict the FEW16’s validity, as it contains psychological questions as much as physical ones. Given the validity of the FEW16, this rather suggests a stronger impact of psychological factors on overall physical well-being than physical ones, in line with our results about the FEW16’s prognostic value. Faller et al., examining the impact of depression and NYHA class on QoL, made the interesting conclusion: ‘in certain patients, Quality of life may depend to a larger extent on the presence and severity of depression rather than on the severity of heart failure’. Taking this into account, the FEW16 seems to be a valid instrument to measure physical well-being in HF patients.

The FEW16, 36-Item Short-Form Health Survey, and PRIME MD Patient Health Questionnaire German short version questionnaires results

The SF36 results from this study confirm the SF36 results published in Scherer et al., where all scores increased significantly during beta-blocker up-titration. All three questionnaires indicate an improvement of QoL and well-being from baseline to FU1, which was mostly annihilated at FU2. This pattern may result from the fact that beta-blocker up-titration happens at the beginning of the study so that changes in well-being and so on are most likely to occur at this stage. Later, patients may get used to their better health and may reflect less consistently on the difference between how they felt at baseline and FU2. Additionally, patients may experience a feeling of being taken care of and of hope for improvement of the illness at the beginning of the study, which, over time, may fade again, although this remains speculation until tested in more detail. An additional effect may result from the reduced number of patients at FU2.

Relation between clinical measurements and FEW16 scores

The negative correlations between heart rate and FEW16 total score and Ability to Enjoy and Resilience are interesting. Heart rate reduction is a therapeutic target of betablocker treatment of HF patients and lower heart rate correlated positively with lower mortality in elderly patients during the CIBIS-ELD trial. The achieved betablocker dose level on the other hand did not predict mortality. Our result that a lower heart rate was associated with better physical well-being seems to point into the same direction. The severity of HF expressed by LVEF and NYHA did not significantly correlate with any of the FEW16 scores, although we found a weak correlation between NYHA class and Resilience. This is consistent with the report by Müller-Tasch et al. that LVEF did not contribute to QoL. Some previous studies found that severity of
HF (i.e. NYHA class) predicts QoL, particularly the physical dimension of QoL. These differing results may be explained by the fact that Faller compared patients of NYHA class I/II with class III/IV, but 95% of our patients were in class I/II with class III/IV, but 95% of our patients were in NYHA class II/III. Thus, the distribution of NYHA classes in our population may have been suboptimal to test for the impact of NYHA class on QoL. The FEW16 should be used on a larger and—regarding NYHA class—one more heterogeneous sample to generate conclusive findings. The significant correlation of major depression with all FEW16 scores reflects the negative impact of depressed mood on the physical and psychological dimension of QoL in HF patients found earlier. Age and sex did not significantly correlate with any FEW16 score. We thus conclude, as did Kolip & Schmidt, that the FEW16 is gender-independent and age-independent. Nevertheless, our study did not show the positive correlation between male sex and Inner Peace that Kolip & Schmidt found in their first validation. Further, we did not find higher FEW16 total scores in men than women, as Albari et al. did in their non-clinical population. Both results may be explained by the difference in health status of the populations examined in the different studies. The 6MWT correlated significantly with Resilience, Inner Peace, and Ability to Enjoy in the whole patient sample. When examined in strata of gender, the FEW16 total score only correlated significantly with the 6MWT in men. This finding needs to be corroborated in a larger sample, but conclusions are intriguing: Are women more decisive in forcing their body to function? Do sexes differ in their perception of feeling physically well? Answers to these questions, some already addressed in clinical studies, may contribute to improve the care of HF patients by applying better tailored strategies to their specific needs.

Relation between changes in FEW16 values and clinical parameters and SF36

Changes in the FEW16 correlated with the changes in both physical and psychological aspects of QoL between baseline and FU2, but not with changes in clinical parameters. Interestingly, although FEW16 Vitality showed a strong correlation with SF36 Vitality and Physical Functioning at baseline, its changes correlated not only with those in Physical Functioning, but also with those of PHQ-D subscales Feeling tired/having little energy and Difficulties sleeping. All FEW16 subscales but Vitality reflected the changes in Little interest/pleasure in doing things and all but Ability to Enjoy for those in Feeling tired/having little energy. Of particular importance, all FEW16 subscales had a tendency to correlate significantly with Thoughts of suicide. Consistently, changes in Inner Peace correlated with changes of more PHQ-D subscales than any other. This underscores that the construct measured by the FEW16 in this trial was highly related to the QoL of our patients.

Impact of psychological vs. physical well-being

The FEW16 total score correlated stronger with the psychological than the physical SF36 component scale. This means

---

Table 5 Correlation coefficients between the changes of FEW16 values and changes of clinical and psychological parameters between baseline and FU2

| Changes between base line and follow-up | Resilience | Ability to Enjoy | Vitality | Inner Peace | FEW16 |
|----------------------------------------|------------|-----------------|---------|-------------|-------|
| Clinical 6 min walking distance         | 0.265      | 0.134           | 0.163   | 0.029       | 0.206 |
| LVEF                                    | -0.153     | 0.135           | 0.032   | -0.123      | 0.024 |
| Heart rate                              | 0.029      | 0.157           | 0.009   | 0.085       | 0.097 |
| SF36 Mental health                      | 0.301**    | 0.462**         | 0.201   | 0.568***    | 0.457*** |
| Psychological, sum                      | 0.401*     | 0.364*          | 0.177   | 0.612***    | 0.455*** |
| Vitality                                | 0.519***   | 0.292           | 0.214   | 0.482***    | 0.453*** |
| Social functioning                      | 0.288      | 0.301*          | 0.178   | 0.429**     | 0.425** |
| Physical functioning                    | 0.197      | 0.278           | 0.371*  | 0.219       | 0.420** |
| Physical, sum                           | 0.271      | 0.220           | 0.213   | 0.304       | 0.377* |
| General health perceptions              | 0.374*     | 0.121           | 0.168   | 0.110       | 0.315* |
| Role — emotional                        | 0.291      | 0.141           | 0.080   | 0.311       | 0.227 |
| Role — physical                         | 0.166      | 0.171           | 0.021   | 0.322**     | 0.224 |
| Pain                                    | 0.197      | -0.075          | 0.184   | 0.054       | 0.108 |
| PHQ-D Little interest or pleasure       | -0.427**   | -0.384*         | -0.211  | -0.307*     | -0.449** |
| Feeling tired or having little energy    | -0.393**   | -0.267          | -0.305* | -0.431**    | -0.439** |
| Difficulties sleeping                   | -0.136     | -0.283          | -0.528**| -0.180      | -0.402** |
| Physical impairments                    | -0.275     | -0.413**        | -0.138  | -0.322*     | -0.385* |
| Thoughts of suicide                     | -0.292     | -0.339*         | -0.253  | -0.398**    | -0.338* |
| Lack of self-confidence                 | -0.251     | -0.288          | -0.112  | -0.394**    | -0.297 |
| Poor appetite or overeating             | -0.117     | -0.212          | -0.153  | -0.173      | -0.262 |
| Feeling down, depressed, hopeless       | -0.213     | -0.184          | -0.133  | -0.368*     | -0.242 |
| Difficulties concentrating on things    | -0.150     | -0.157          | -0.071  | -0.213      | -0.141 |

***P < 0.001, **P < 0.01, *P < 0.05.

SF36, 36-Item Short-Form Health Survey; PHQ-D, PRIME MD Patient Health Questionnaire German short version; LVEF, left ventricular ejection fraction.
that the management team needs to be aware of the psychological and social situation of the patients in order to be able to best support patients’ overall well-being. At the same time, it needs to be acknowledged that the interdependency between these factors requires more research. Back in 1977, George L. Engel with his biopsychosocial model was first requesting to include a more holistic view of the patient into the definition and treatment of health and disease. In 2004, Yolanda Alonso published a study where she investigated the frequency of inclusion of this concept into research papers and found no increase between the periods of 1978–82 and 1996–2000. Our results once more strengthen the view that more factors impact on patient health than assessed through clinical measurements and that they should be included into treatment and research.

**Conflict of Interest**

H.-D.D. reported receiving research grant support and travel support from Merck KGaA and equipment provision support from Merck KgA, Roche, and Biosite. E.T. reported receiving support from Merck KgA, Getemed AG, and ResMed. For all other authors, there is nothing to declare.

**Funding**

The CIBIS-ELD trial (ISRCTN34827306) was supported by the German government (Federal Ministry of Education and Research (BMBF01GI0205) and the DAAD German Academic Exchange Service (D/08/2077)). Furthermore, this trial was sponsored by MERCK KgA, GETEMED AG, Brahms GmbH, and Roche.

**References**

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596–602.

2. Fonarow GC. Epidemiology and risk stratification in acute heart failure. Am Heart J 2008; 155: 200–207.

3. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey WL, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202.

4. Gheorghie M, Brouwer WB, van Baal PH. Quality of life and time to death: have the health gains of preventive interventions been underestimated? Med Decis Making 2015; 35: 316–327.

5. Konstam MA, Yusuf S. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigators. Studies of Left Ventricular Dysfunction Investigators. Am J Cardiol 1996; 78: 890–895.

6. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation 2004; 110: 546–551.

7. Scherer M, Düngen HD, Inkrot S, Tahirović E, Lashki DJ, Apostolović S, Edelmann F, Wachter R, Loncar G, Haverkamp W, Neskovic A, Herrmann-Lingen C. Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). Eur J Intern Med 2013; 24: 333–338.

8. Düngen HD, Musial-Bright I, Lashki DJ, Apostolović S, Edelmann F, Wachter R, Neskovic A, Herrmann-Lingen C. Determinants of change in quality of life in the Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD). Eur J Intern Med 2013; 24: 333–338.

9. Anker SD, Agewall S, Borgeflee M, Calvert M, Jaime CJ, Cowie MR, Ford I, Parry JA, Riley JP, Swedberg K, Tavazzi L, Wiklund I, Kirchhof P. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J 2014; 35: 2001–2009.

10. Müller-Tasch T, Peters-Klimm F, Schellberg D, Holzapfel N, Bart A, Jünger S, Zscesenyi J, Herzog W. Depression is a major determinant of quality of life in patients with chronic systolic heart failure in general practice. J Card Fail 2007; 13: 818–824.

11. Faller H, Stöck S, Schuler M, Schowalter K, Abseldin M, Angermann CE. Depression and disease severity as predictors of health-related quality of life in patients with chronic heart failure—a structural equation modeling approach. J Card Fail 2009; 15: 286–292.

12. McNaier DM, Lon M, Doppelmann LF. Manual for the Profile of Mood States. 27. San Diego, CA: Educational and Industrial Testing Service; 1971.

13. Faller H, Stöck S, Schuler M, Schowalter K, Abseldin M, Angermann CE. Depression and disease severity as predictors of health-related quality of life in patients with chronic heart failure—a structural equation modeling approach. J Card Fail 2009; 15: 286–292.

14. McNaier DM, Lon M, Doppelmann LF. Manual for the Profile of Mood States. 27. San Diego, CA: Educational and Industrial Testing Service; 1971.

15. Hunt SM, McEwen J, McKenna SP. Measuring Health Status. Beckenham, Kent: Croom Helm; 1986.

16. Hinz A, Klaiber B, Schramm J, Brähler E. The psychometric quality of the Nottingham Health Profile (NHP) in the general population. Psychother Psychosom Med Psychol 2003; 53: 353–358.

17. Becker P. Theoretische Grundlagen. In Abele A, Becker P, eds. Wohlbefinden: Theorie - Empirie - Diagnostik; 1999. Weinheim: Juventa, 13–50.

18. Albaní C, Blaser G, Geyer M, Schmutzer G, Hinz A, Bailer H, Grukle N, Brähler E. Validation and standardization of the 'Questionnaire for Assessing Subjective Physical Well-Being' by Kolop and Schmiedt in a representative German sample. Psychother Psychosom Med Psychol 2006; 56: 172–181.

19. Bullinger M, Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe, 1998.

20. Bullinger M, Kirchberger I. Der SF-36- Fragebogen zum Gesundheitszustand: Handbuch für die deutschsprachige Fragebogenversion. Göttingen: Hogrefe, 1997.

21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992; 30: 473–483.

22. Morfeld M, Bullinger M, Nantke J, Brähler E. The version 2.0 of the SF-36 health survey: results of a population-representative study. Soz Praventivmed 2005; 50: 292–300.

23. Bullinger M. German translation and psychometric testing of the SF-36 health survey: preliminary results from the IQOLA Project. International Quality of Life Assessment. Soc Sci Med 1995; 41: 1359–1366.
Validation of FEW16 questionnaire for HF patients

24. Kurth BM, Ellert U. The SF-36 questionnaire and its usefulness in population studies: results of the German Health Interview and Examination Survey 1998. Soz Praventivmed 2002; 47: 266–277.

25. Maurischat C, Ehlebracht-Konig I, Kuhn A, Bullinger M. Structural validity of the Short Form 36 (SF-36) in patients with rheumatic diseases. Z Rheumatol 2005; 64: 255–264.

26. Briem D, Linhart W, Lehmann W, Bullinger M, Schoder V, Meenen NM, Windolf J, Rueger JM. Investigation of the health-related quality of life after a dorso ventral stabilization of the thoracolumbar junction. Unfallchirurg 2003; 106: 625–632.

27. Bullinger M, Morfeld M, Kohlmann T, Namke J, van den Bussche H, Dott B, Dunkelberg S, Kirchberger I, Krüger-Boedecker A, Lachmann A, Lang K, Mathis C, Mittag O, Peters A, Raspe HH, Schulz H. SF-36 health survey in rehabilitation research. Findings from the North German Network for rehabilitation research, NVRF, within the rehabilitation research funding program. Rehabilitation (Stuttg) 2003; 42: 218–225.

28. Riedmayr MI, Tammen AR, Behr TM, Wittig C, Bullinger M, Reichart B, Angermann CE. Perspectives of patients with terminal renal failure: quality of life and psychological adjustment before and in the first year after heart transplantation. Z Kardiol 1998; 87: 808–816.

29. Piehlmeier W, Bullinger M, Kirchberger I, Land W, Landgraf R. Evaluation of the quality of life of patients with insulin-dependent diabetes mellitus before and after organ transplantation with the SF 36 health survey. Eur J Surg 1996; 162: 933–940.

30. Bullinger M. Assessment of health related quality of life with the SF-36 health survey. Rehabilitation (Stuttg) 1996; 35: XVII–XXVII.

31. Walach HGC. Die psychometrischen Eigenschaften des deutschen MOS-SF-36 Health Surveys. Eine Analyse anhand von Akupunkturpatienten. Zeitschrift für Gesundheitswissenschaften 2001; 9: 242–260.

32. von Steinbüchel N, Wilson L, Gibbons H, Hawthorne G, Höfer S, Schmidt S, Bullinger M, Maas A, Neugebauer E, Powell J, von Wild K, Zitnay G, Bakx W, Christensen AL, Koskinen S, Formisano R, Saarajuri J, Sasse N, Truelle JL. Quality of life after brain injury (QOLIBRI) task force: scale validity and correlates of quality of life. J Neurotrauma 2010; 27: 1157–1165.

33. Faller H, Steinbuechel T, Schwalter M, Spertus JA, Stork S, Angermann CE. The Kansas City Cardiomyopathy Questionnaire (KCCQ) – a new disease-specific quality of life measure for patients with chronic heart failure. Psychother Psychosom Med Psychol 2005; 55: 200–208.

34. Gräfe K, Zipfel S, Herzog W, Löwe B. Screening psychischer Störungen mit dem "Gesundheitsfragebogen für Patienten (PHQ-D)". Ergebnisse der deutschen Validierungsstudie. Diagnostica 2004; 50: 171–181. 2014.

35. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 1999; 282: 1737–1744.

36. Löwe B, Spitzer RL, Zipfel S, Herzog W. PHQ-D Gesundheitsfragebogen für Patienten 2. Auflage, Manual Komplettversion und Kurzform. Autorisierte deutsche Version des "Prime MD Patient Health Questionnaire (PHQ)" 2002, Pfizer. 2002.

37. Löwe B, Spitzer RL, Gräfe K, Kroenke K, Quenter A, Zipfel S, Buchholz C, Witte S, Herzog W. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord 2004; 78: 131–140.

38. Lowe B, Grafe K, Zipfel S, Witte S, Loerch B, Herzog W. Diagnosing ICD-10 depressive episodes: superior criterion validity of the patient health questionnaire. Psychother Psychosom 2004; 73: 386–390.

39. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606–613.

40. Ancheta IB, Battie C, Cobb S, Ancheta C, Miller A, Chiong JR. The impact of B-type natriuretic peptide, New York Heart Association classification and depression on quality of life in nonhospitalized heart failure patients. Prog Cardiovasc Nurs 2009; 24: 124–130.

41. Costello JA, Boblin S. What is the experience of men and women with congestive heart failure? Can J Cardiovasc Nurs 2004; 14: 9–20.

42. Heo S, Moser DK, Widener J. Gender differences in the effects of physical and emotional symptoms on health-related quality of life in patients with heart failure. Eur J Cardiovasc Nurs 2007; 6: 146–152.

43. Willener R, Hantikainen V. Individual quality of life following radical prostatectomy in men with prostate cancer. Urol Nurs 2005; 25: 88–100.

44. Alonso Y. The biopsychosocial model in medical research: the evolution of the health concept over the last two decades. Patient Educ Couns 2004; 53: 239–244.

45. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196: 129–136.

DOI: 10.1002/ehf2.12045